Jingyi Li

Jingyi Li is currently a Senior Global Medical Affairs Lead at AstraZeneca, specializing in lung cancer therapies, including Trastuzumab deruxtecan and Osimertinib. With a background that includes roles as Research Scientist and Medical Director within AstraZeneca's Global Epidemiology and Patient Safety sectors, Jingyi has contributed to major portfolios in respiratory and oncology products. Prior to their tenure at AstraZeneca, Jingyi worked as an Epidemiologist at the University of Maryland Medical Center, focusing on trauma and injury epidemiology. Jingyi is pursuing a PhD at the University of Maryland School of Medicine and holds an MB from Beijing, China.